Venture NAV Tracker / Private company
MoonLake Immunotherapeutics
Headquarters—
Founded—
Last known round—
Reported valuation—
Cross-fund comparison
Equity & warrant marks
One latest disclosed mark per fund.
| Fund | Fair value | Security / basis | Implied price / share | Mark age vs round | Methodology / filing |
|---|---|---|---|---|---|
| HTGCHercules Capital, Inc. | $1.8MMar 31, 2026 · source ↗ | equityFair Value | $18.64Mar 31, 2026 · source ↗ | —Mar 31, 2026 · source ↗ | 10-Q 2026-03-31 ↗ |
Cross-fund comparison
Debt investments
One latest disclosed debt mark per fund.
| Fund | Security type / basis | Principal | Fair value | FV / principal | Rate | Maturity | Mark age vs round | Non-accrual |
|---|---|---|---|---|---|---|---|---|
| HTGCHercules Capital, Inc. | senior secured loanFair Value — Senior Secured | $46MMar 31, 2026 · source ↗ | $46MMar 31, 2026 · source ↗ | 100.0%Mar 31, 2026 · source ↗ | Prime + 1.45 %, Floor rate 8.45 %, 6.95 % Exit FeeMar 31, 2026 · source ↗ | Apr 1, 2030Mar 31, 2026 · source ↗ | —Mar 31, 2026 · source ↗ | NoMar 31, 2026 · source ↗ |
Historical marks
Reported fair value by fund
Each bar is a disclosed position-quarter.